News & Events
November 24, 2020
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced a strategic development agreement with Translational Drug Development (TD...
Read More
October 29, 2020
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices
Translational Drug Development (TD2), a precision oncology contract research organization (CRO), and VieCure have announced a strategic partnership that will provide patients receiving care in communi...
Read More
September 28, 2020
Applied Clinical Trials: Small Biopharma and CROs: Seeking Stronger Synergies
Many emerging biopharmaceutical companies hire contract research organizations (CROs) because of limited staffing and regulatory experience to help them navigate the regulatory pathway. CROs are ...
Read More
July 16, 2020
Ready to Make an Impact? Join Our Team.
With a team of experts that bring their own unique knowledge, insight and experience to the table, TD2 is looking for new candidates that share our vision to find cures and relief for cancer patients ...
Read More
